Delphia (USA)’s Rubius Therapeutics, Inc RUBY Stock Holding History

Delphia (USA)’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,057	Closed	-$61K	–	521
2022 Q1	$61K	Buy	+11,057	New	+$70.2K	0.05%	316

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFM

Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Delphia (USA)'s RUBY Position: Q2 2022 in Review

Delphia (USA) sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 11,057 shares — an estimated $61K sold.

Delphia (USA) first reported a position in RUBY in Q1 2022 and held it in 1 quarter. The position peaked at $61K in Q1 2022. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

Delphia (USA) reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
Delphia (USA) sold 11,057 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $61K.
Delphia (USA) first reported a position in Rubius Therapeutics, Inc in Q1 2022 and held it in 1 quarter.
Delphia (USA)'s Rubius Therapeutics, Inc position peaked at $61K in Q1 2022.
72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Delphia (USA)'s 13F filing for Q2 2022, filed 15 Aug 2022.